BEACON (2013) — Trial Summary
BEACON (2013): The trial evaluating bardoxolone methyl in patients with type 2 diabetes and stage 4 CKD was terminated early due to an increased risk of heart failure and cardiovascular events, despite improvements in eGFR.
References
- de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26):2492-2503.